CN Patent

CN1950078A — 使用glp－1激动剂抵抗药物诱发的肥胖

Assigned to Novo Nordisk AS · Expires 2007-04-18 · 19y expired

What this patent protects

本发明描述了通过给予GLP－1激动剂而治疗由于施用诱发肥胖的药物导致的肥胖。

USPTO Abstract

本发明描述了通过给予GLP－1激动剂而治疗由于施用诱发肥胖的药物导致的肥胖。

Drugs covered by this patent

Patent Metadata

Patent number
CN1950078A
Jurisdiction
CN
Classification
—
Expires
2007-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.